Dacogen ASCO abstracts
[all poster discussions]
Monday, 5/16/2005, 1:30 - 5:30pm Clinical benefit and survival endpoints from a phase III trial comparing decitabine (DAC) vs supportive care (SC) in patients with advanced myelodysplastic syndromes (MDS)[ ?pivotal filing study?
Presenter: Hussain I Saba, MD, PhD
Monday, 5/16/2005, 1:30 - 5:30pm Decitabine low-dose schedule (100 mg/m2/course) in myelodysplastic syndrome (MDS). Comparison of 3 different dose schedules
Susan O'Brien, MD
Monday, 5/16/2005, 1:30 - 5:30pm Hypomethylation induction in MDS after treatment with decitabine at three different doses
Presenter: Yashuhiro Oki, MD
Sunday, 5/15/2005, 8:00 - 12:00pm Phase I trial of sequential decitabine plus high-dose interleukin-2 (HD IL-2) in patients with advanced melanoma Presenter: Jared Gollob, MD
Poster Discussion Sessions Melanoma Details ... Level 2, Hall F3
Monday, 5/16/2005, 8:00 - 12:00pm
A phase I study of decitabine (DCT) in combination with doxorubicin (DOX) and cyclophosphamide (CTX) in the treatment of relapsed or refractory solid tumors: A Children’s Oncology Group Study Presenter: Rani E. George, MD, PhD
|
